Interstitial Lung Disease in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A European Multicenter Study
At baseline, higher fibrosis severity, UIP, and lower FVC% were associated with worse outcomes. Immunosuppressives, such as rituximab, may help preserve lung function. The need for early identification and individualized treatment in ILD associated with AAV or ANCA is underscored.
Authors
- S. Monti (ORCID: https://orcid.org/0009-0000-5816-6562)
- M. Kotnik (ORCID: https://orcid.org/0000-0003-3388-9283)
- Ioannis Petrakis (ORCID: https://orcid.org/0000-0002-0095-9823)
- Aglaia Chalkia (ORCID: https://orcid.org/0000-0002-5963-3246)
- Kostas Stylianou
- Viral Jayshinh Nanda
- C. Mukhtyar
- Ashnish Sinha (ORCID: https://orcid.org/0000-0003-1261-5259)
- Pasupathy Sivasothy
- Ajay R Kamath
- Dimitrios Petras
- Aladdin J. Mohammad
- Rona M Smith
- Spyridon Katechis
- Dimitrios Vassilopoulos
- Timothy J Sadler
- David Jayne
- Rachel Jones
Institutions
- University of Milan (IT)
- National and Kapodistrian University of Athens (GR)
- University of Cambridge (GB)
- Norfolk and Norwich University Hospital (GB)
- Norfolk and Norwich University Hospitals NHS Foundation Trust (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- IRCCS Istituto Auxologico Italiano (IT)
- Skåne University Hospital (SE)
- University Hospital of Heraklion (GR)
- Hippocration General Hospital (GR)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1002/art.70078
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health and Care Research Wales
- National Institute for Health and Care Research
- University of Cambridge
- Cambridge University Hospitals
- Stavros Niarchos Foundation
- NIHR Cambridge Biomedical Research Centre